MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen
by Kim Johansen · The Markets DailyMaxCyte (NASDAQ:MXCT – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Tuesday.
A number of other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Craig Hallum lowered their price target on MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MaxCyte has a consensus rating of “Hold” and an average price target of $5.50.
View Our Latest Analysis on MaxCyte
MaxCyte Price Performance
Shares of MXCT stock opened at $0.74 on Tuesday. The firm has a fifty day moving average of $0.81 and a two-hundred day moving average of $1.30. The firm has a market cap of $79.51 million, a P/E ratio of -1.73 and a beta of 1.23. MaxCyte has a 1-year low of $0.64 and a 1-year high of $2.96.
MaxCyte (NASDAQ:MXCT – Get Free Report) last issued its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $6.76 million for the quarter, compared to analyst estimates of $9.16 million. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 22.15%. On average, sell-side analysts expect that MaxCyte will post -0.42 EPS for the current year.
Hedge Funds Weigh In On MaxCyte
Institutional investors have recently modified their holdings of the company. Mirabella Financial Services LLP lifted its position in MaxCyte by 78.4% in the 2nd quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company’s stock valued at $14,388,000 after purchasing an additional 2,900,000 shares during the last quarter. Virtu Financial LLC bought a new position in MaxCyte in the 4th quarter worth about $67,000. BNP Paribas Financial Markets increased its stake in shares of MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after purchasing an additional 18,913 shares during the period. State of Wyoming bought a new stake in shares of MaxCyte during the second quarter valued at approximately $38,000. Finally, Prudential Financial Inc. acquired a new position in shares of MaxCyte during the second quarter worth approximately $26,000. Institutional investors own 68.81% of the company’s stock.
MaxCyte Company Profile
MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.